Does research from clinical trials in metastatic hormone-sensitive prostate cancer treatment translate into access to treatments for patients in the 'real world'? a systematic review
Affiliation
Clinical Effectiveness Unit, Royal College of Surgeons, London, UK; London School of Hygiene and Tropical Medicine, London, UKIssue Date
2023
Metadata
Show full item recordAbstract
Context: Since 2015 there have been major advances in the management of primary metastatic hormone-sensitive prostate cancer (mHSPC) following the publication of key clinical trials that demonstrated significant clinical benefits with docetaxel chemotherapy or novel hormone therapy (NHT) in addition to androgen deprivation therapy (ADT). Despite these advances, there is evidence to show that these treatments are not being utilised for mHSPC in clinical practice. Objective: To determine the utilisation of docetaxel and NHT in mHSPC in routine practice and the determinants of variation in their use. Evidence acquisition: MEDLINE and Embase were searched systematically for studies on utilisation of treatments for primary mHSPC that were based on regional or national data sets and published after January 2005. Study results were summarised using a narrative synthesis. Evidence synthesis: Thirteen papers were included in the analysis, six full-text articles and seven abstracts, on studies that included a total of 166 876 patients. The utilisation rate of treatment intensification with either docetaxel or NHT (enzalutamide, apalutamide, or abiraterone) in addition to ADT ranged from 9.3% to 38.1% across the studies. Younger, White patients with fewer comorbidities and living in more urban settings were more likely to be prescribed treatment intensification. Patients treated in private academic institutions by oncologists were more likely to receive docetaxel or NHT. Socioeconomic status did not impact receipt of systemic therapy. NHT utilisation rates appear to have increased over time. Conclusions: These results highlight the need to change the approach to the treatment of primary mHSPC in the real world by harnessing the practice-changing results from recent trials in this setting to optimise upfront systemic therapy for this patient population.Citation
Dodkins J, Nossiter J, Cook A, Payne H, Clarke N, van der Meulen J, et al. Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the "Real World"? A Systematic Review. European urology oncology. 2023 Jun 27. PubMed PMID: 37380578. Epub 2023/06/29. eng.Journal
European Urology OncologyDOI
10.1016/j.euo.2023.05.002PubMed ID
37380578Additional Links
https://dx.doi.org/10.1016/j.euo.2023.05.002Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.euo.2023.05.002